1. Targeting Integrin α4β7 in Steroid-Refractory Intestinal Graft-versus-Host Disease 
Yngvar Fløisand, Knut E.A. Lundin, Vladimir Lazarevic, Jørn Dehli Kristiansen, Liv T.N. Osnes, Geir E. Tjønnfjord, Henrik Mikael Reims, Tobias Gedde-Dahl 
Biology of Blood and Marrow Transplantation 
Volume 23, Issue 1, Pages (January 2017)
DOI: /j.bbmt
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Colonic biopsies in patients 1, 2, and 3 before (a, c and e) and after (b, d and f) treatment with vedolizumab. Patient 1 had substantial crypt loss and some remaining and regenerating crypts with a few apoptotic bodies, corresponding to GVHD grade III (a). Biopsies taken after vedolizumab showed prominent regenerative changes with crypt branching, crowding, and very few apoptotic bodies. Some areas still lacked crypts and were edematous with capillary dilatation and proliferation and iron-laden macrophages (b). In patient 2, pretreatment biopsies showed erosions and substantial crypt loss, inflammation, and marked apoptosis in the remaining crypts, corresponding to GVHD grade III (c). After vedolizumab, histology showed crypt regeneration and branching with reactive epithelial changes and no apoptosis or inflammation (d). In patient 3, pretreatment biopsies showed large eroded areas with crypt loss, numerous apoptotic cells in remaining crypts, and edematous lamina propria with capillary proliferation and scattered neutrophils, eosinophils, and mononuclear cells. The findings corresponded to GVHD grades III to IV. Immunohistochemical stain for cytomegalovirus showed a single positive cell nucleus (e). After treatment there was focal absence of crypts and regenerating and branching crypts but still a few apoptotic cells (f). Except for 1 positive nucleus in patient 3 pretreatment, all cases were negative for cytomegalovirus on immunohistochemical stains.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Endoscopic findings in patients 1, 2, and 3. Duodenal mucosa pretreatment (a, b, and c) and after 3 doses of vedolizumab (d, e, and f). In all 3 cases, global and complete villous atrophy can be seen before treatment. The post-treatment slides all show improvement. Colonic mucosa in patient 1 pretreatment (g) and after 3 doses (j). Before treatment, normal mucosa was not seen, only ulcerations, damaged mucosa, and spontaneous bleeding. After treatment, one can see regenerating mucosa and ulcerations. Ileal mucosa in patient 2 pre- and post-treatment (h, k) and colonic mucosa in patient 3 pre- and post-treatment (i, l), where the pretreatment slides show complete loss of mucosa and the post-treatment slides show regeneration of mucosa (the picture was taken after a biopsy, hence the visible blood).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions